MOBILIZATION OF CIRCULATING HEMATOPOIETIC STEM-CELLS WITH GRANULOCYTE-COLONY-STIMULATING FACTOR AFTER CHEMOTHERAPY IN PATIENTS WITH MULTIPLE-MYELOMA

被引:0
作者
OHLER, L
SCHOLTEN, C
REITER, E
TIEFENGRABER, E
JAGER, U
STROBL, H
LECHNER, K
HOCKER, P
GEISSLER, K
机构
[1] UNIV VIENNA,AKH,INNERE MED KLIN 1,HAMATOL & HAMOSTASEOL ABT,A-1090 VIENNA,AUSTRIA
[2] AKH,INTENSIVBLUTBANK,VIENNA,AUSTRIA
[3] UNIV VIENNA,INST IMMUNOL,A-1010 VIENNA,AUSTRIA
[4] SOZIALMED ZENTRUM OST,MED ABT 2,VIENNA,AUSTRIA
关键词
MULTIPLE MYELOMA; STEM CELL MOBILIZATION; G-CSF; LEUKAPHERESIS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Due to the relatively low tumour cell contamination of peripheral blood in patients with multiple myeloma, autologous transplantation of circulating stem cells may have theoretical advantages over autologous bone marrow transplantation. In four patients with multiple myeloma who where considered potential candidates for autologous stem cell transplantation G-CSF (600 mug/day) was administered following chemotherapy in order to maximally increase the number of circulating progenitor cells during haematopoietic rebound and to facilitate progenitor cell harvest by leukapheresis. In two previously untreated patients the administration of G-CSF following chemotherapy according to the UVA protocol (ultralan, vincristine, adriamycin) greatly increased circulating haematopoietic stem cells from 247 to 7552 CFU-GM/ml in patient 1 and from 173 to 6361 CFU-GM/ml in patient 2, which by far exceeded the increase in progenitor cells following chemotherapy alone, namely only to 594 and 317 CFU-GM/ml in patient 1 and patient 2, respectively. In two repeatedly pretreated patients, the combination of UVA and G-CSF was much less effective. Progenitor cells increased from 144 to 735 CFU-GM/ml in patient 3 and only from 222 to 232 CFU-GM/ml in patient 4. In both cases, however, mobilization of haematopoietic progenitor cells by G-CSF following cyclophosphamide (50 and 70 mg/kg body weight, respectively) led to much higher CFU-GM peak values (5324 in patient 3 and 2245 in patient 4), thus allowing an adequate harvest of mononuclear cells and CD 34+ cell numbers to achieve, in all probability, the prompt and complete reconstitution of haematopoiesis in case of transplantation. The combination of UVA and G-CSF is an effective strategy to mobilize haematopoietic progenitor cells in previously untreated patients with multiple myeloma, but seems to be relatively ineffective in patients who have received prior chemotherapy. Due to its higher efficacy the combination of cyclophosphamide and G-CSF is the preferred mode of treatment in such patients.
引用
收藏
页码:580 / 584
页数:5
相关论文
共 50 条
  • [41] Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide plus /- Plerixafor versus Granulocyte Colony-Stimulating Factor plus /- Plerixafor in the Lenalidomide Era
    Johnsrud, Andrew
    Ladha, Abdullah
    Muffly, Lori
    Shiraz, Parveen
    Goldstein, Gary
    Osgood, Victoria
    Shizuru, Judith A.
    Johnston, Laura
    Arai, Sally
    Weng, Wen-Kai
    Lowsky, Robert
    Rezvani, Andrew R.
    Meyer, Everett H.
    Frank, Matthew J.
    Negrin, Robert S.
    Miklos, David B.
    Sidana, Surbhi
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (07): : 590.e1 - 590.e8
  • [42] Granulocyte colony stimulating factor-producing multiple myeloma associated with neutrophilia
    Kohmura, K
    Miyakawa, Y
    Kameyama, K
    Kizaki, M
    Ikeda, Y
    LEUKEMIA & LYMPHOMA, 2004, 45 (07) : 1475 - 1479
  • [43] ENHANCED EFFECT OF MUTANT GRANULOCYTE-COLONY-STIMULATING FACTOR (KW-2228) ON THE GROWTH OF NORMAL AND LEUKEMIC HEMATOPOIETIC PROGENITOR CELLS IN COMPARISON WITH RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF)
    SUZUKI, T
    TOHDA, S
    NAGATA, K
    IMAI, Y
    MUROHASHI, I
    NARA, N
    ACTA HAEMATOLOGICA, 1992, 87 (04) : 181 - 189
  • [44] Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation
    Chow, Signy
    Lazo-Langner, Alejandro
    Ormond, George
    Howson-Jan, Kang
    Xenocostas, Anargyros
    JOURNAL OF CLINICAL APHERESIS, 2013, 28 (04) : 285 - 292
  • [45] Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation
    Ivetta Danylesko
    Rina Sareli
    Nira Varda-Bloom
    Ronit Yerushalmi
    Noga Shem-Tov
    Hila Magen
    Avichai Shimoni
    Arnon Nagler
    International Journal of Hematology, 2021, 114 : 363 - 372
  • [46] Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
    Dwight D. Eplin
    Anna D. Jackson
    Austin M. Smith
    Brent Salvig
    Wichai Chinratanalab
    Bipin N. Savani
    Clinical Hematology International, 2019, 1 (4) : 229 - 233
  • [47] OPTIMAL BLOOD STEM-CELL MOBILIZATION USING 10 MU-G/KG GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) ALONE FOR HIGH-DOSE MELPHALAN INTENSIFICATION IN MULTIPLE-MYELOMA - AN INTRAPATIENT CONTROLLED-STUDY
    FEREMANS, W
    LEMOINE, F
    RAVOET, C
    LAMBERMONT, M
    BASTIN, G
    DELVILLE, JP
    PRADIER, O
    DUPONT, E
    CAPEL, P
    AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (02) : 135 - 138
  • [48] Loss of RUNX1 function results in enhanced granulocyte-colony-stimulating factor-mediated mobilization
    Lam, K.
    Muselman, A.
    Du, R.
    Yan, M.
    Matsuura, S.
    Zhang, D-E
    BLOOD CANCER JOURNAL, 2016, 6 : e407 - e407
  • [49] A case of multiple myeloma producing granulocyte colony-stimulating factor
    Usuda, H
    Naito, M
    Ohyach, K
    Iizumi, A
    PATHOLOGY INTERNATIONAL, 1997, 47 (12) : 866 - 869
  • [50] Granulocyte colony-stimulating factor utilization postautologous hematopoietic stem cell transplant in multiple myeloma patients: Does one size fit all?
    Jackson, Emily R.
    Jared, Jason R.
    Piccolo, Jennifer K.
    Woo, Kaitlin M.
    Mably, Mary S.
    Reed, Michael P.
    Callander, Natalie S.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (05) : 1135 - 1141